Office of the Director, National Institutes of Health; Notice of Meeting, 66053-66054 [E8-26432]

Download as PDF Federal Register / Vol. 73, No. 216 / Thursday, November 6, 2008 / Notices Contact Person: Margaret Weidman, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3AN18B, Bethesda, MD 20892, 301–594–3663, weidmanma@nigms.nih.gov. Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel. NIH Pathway to Independence Awards. Date: December 2, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Meredith D. TempleO’Connor, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3AN12C, Bethesda, MD 20892, 301–594– 2772, templeocm@mail.nih.gov. Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel, ZGM1 PPBC–6 (AN). Date: December 2, 2008. Time: 8:30 a.m. to 1 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Natcher Building, Room 3AN18, 45 Center Drive, Bethesda, MD 20892. (Telephone Conference Call). Contact Person: Carole H. Latker, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Natcher Building, Room 3AN–18, Bethesda, MD 20892, (301) 594–2848, latkerc@nigms.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS) Dated: October 29, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–26332 Filed 11–5–08; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES sroberts on PROD1PC70 with NOTICES National Institutes of Health National Institute of Dental & Craniofacial Research; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. VerDate Aug<31>2005 19:11 Nov 05, 2008 Jkt 217001 The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel, R25 grant application review. Date: December 11, 2008. Time: 2 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Sooyoun (Sonia) Kim, MS, Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, NIDCR/NIH, 6701 Democracy Blvd, Rm 675, Bethesda, MD 20892–4878, (301) 594–4827, kims@email.nidr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS) Dated: October 30, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–26433 Filed 11–5–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: Recombinant DNA Advisory Committee. Date: December 3–4, 2008. Time: December 3, 2008, 9:30 a.m. to 5:30 p.m. Agenda: The Recombinant DNA Advisory Committee will review and discuss selected PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 66053 human gene transfer protocols as well as related data management activities. Please check the meeting agenda at http: // www4.od.nih.gov/oba/RAC/meeting.htm for more information. Place: National Institutes of Health, The Fishers Lane Conference Center, 5635 Fishers Lane, Terrace Level Conference Room, Rockville, MD 20852. Time: December 4, 2008, 8 a.m. to 1 p.m. Agenda: The Recombinant DNA Advisory Committee will review and discuss selected human gene transfer protocols including a gene transfer protocol for X–SCID as well as related data management activities. Please check the meeting agenda at http:// www4.od.nih.gov/oba/RAC/meeting.htm for more information. Place: National Institutes of Health, The Fishers Lane Conference Center, 5635 Fishers Lane, Terrace Level Conference Room, Rockville, MD 20852. Contact Person: Lisa A. Parker, Advisory Committee Coordinator, Office of Science Policy, Office of Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Suite 750–A1, Bethesda, MD 20892, 301–496–9838, parkerla@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: http:// www4.od.nih.gov/oba/, where an agenda and any additional information for the meeting will be posted when available. OMB’s ‘‘Mandatory Information Requirements for Federal Assistance Program Announcements’’ (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers virtually every NIH and Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected. (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan E:\FR\FM\06NON1.SGM 06NON1 66054 Federal Register / Vol. 73, No. 216 / Thursday, November 6, 2008 / Notices Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS) Dated: October 30, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–26432 Filed 11–5–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Proposed Collection; Comment Request In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer on (240) 276– 1243. Comments are invited on: (a) Whether the proposed collections of information are necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Proposed Project: Enhancing Substance Abuse Treatment Services To Address Hepatitis Infection Among Intravenous Drug Users Hepatitis Testing and Vaccine Tracking Form—In Use Without OMB Approval The Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center Substance Abuse Treatment (CSAT), is requesting an OMB approval of a Hepatitis Testing and Vaccine Tracking Form for the prevention of Viral Hepatitis in patients in designated OTPs. This form is similar to the Minority AIDS Initiative HIV Rapid Testing Clinical Form that received an emergency approval (OMB No. 0930–0295) in September 2008. This form will allow SAMHSA/CSAT to collect essential Clinical information that will be used for quality assurance, quality performance and product monitoring on approximately 264 Rapid Hepatitis C Test kits and 10,628 doses of hepatitis vaccine (Twinrix, HAV, or HBV). The above kits and vaccines will be provided to designated OTPs serving the minority population in their communities. The information collected on the Form will solicit and reflect the following information: • Demographics (age, gender, ethnicity) of designated OTP site; • History (Screening) of Hepatitis C exposure; • Results of Rapid Hepatitis C Testing (Kit) and Follow-up information; • Service Provided (type of vaccine given) Divalent vaccine (Twinrixcombination HAV and HBV) or Monovalent vaccine (HAV or/and HBV); • Substance Abuse Treatment Outcomes (Information regarding the beginning, continuing or completion of vaccination series); • Type of Referral Services Indicated (i.e., Gastroenterology, TB; Mental Health, Counseling, Reproductive/ Prenatal, etc.); This program is authorized under Section 509 of the Public Health Service (PHS) Act [42 U.S.C. 290bb–2]. The purpose of the form is to increase the screening and reporting of viral hepatitis in high risk minorities in OTPs. The information collected will allow SAMHSA to address the increased morbidity and mortality of hepatitis in minorities being treated for drug addiction. The SAMHSA/CSAT Hepatitis Testing and Vaccine Tracking Form would support quality of care, provide minimum but adequate clinical and product monitoring, and provide appropriate safeguards against fraud, waste and abuse of Federal funds. The table below reflects the annualized hourly burden. Number of respondents screened Responses/ respondent Burden hours Total burden hours 50,000 .......................................................................................................................................... 1 0.05 2,500 Send comments to Summer King, SAMHSA Reports Clearance Officer, Room 7–1044, One Choke Cherry Road, Rockville, MD 20857 and e-mail her a copy at summer.king@samhsa.hhs.gov. Written comments should be received within 60 days of this notice. Dated: October 30, 2008. Elaine Parry, Acting Director, Office of Program Services. [FR Doc. E8–26471 Filed 11–5–08; 8:45 am] sroberts on PROD1PC70 with NOTICES BILLING CODE 4162–20–P VerDate Aug<31>2005 19:11 Nov 05, 2008 Jkt 217001 DEPARTMENT OF HOMELAND SECURITY Coast Guard [Docket No. USCG–2008–1040] Navigation Safety Advisory Council; Meeting Coast Guard, DHS. Notice of meeting. AGENCY: ACTION: SUMMARY: The Navigation Safety Advisory Council (NAVSAC) will meet in Washington, DC, to discuss various issues relating to the safety of navigation. The meeting will be open to the public. DATES: NAVSAC will meet on Wednesday, December 10, 2008, from 8 a.m. to 5 p.m. and Thursday, December PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 11, 2008 from 8 a.m. to 5 p.m. The meeting may close early if all business is finished. Written material and requests to make oral presentations should reach the Coast Guard on or before November 24, 2008. Requests to have a copy of your material distributed to each member of the committee should reach the Coast Guard on or before November 24, 2008. ADDRESSES: NAVSAC will meet at the Courtyard by Marriott Capital Hill/Navy Yard, 104 L Street, SE., Washington, DC 20003. Send written material and requests to make oral presentations to Mr. John Bobb, the Assistant Designated Federal Officer (ADFO), Commandant (CG–54121), U.S. Coast Guard Headquarters, 2100 Second Street, SW., Washington, DC 20593–0001. This notice is available on our online docket, E:\FR\FM\06NON1.SGM 06NON1

Agencies

[Federal Register Volume 73, Number 216 (Thursday, November 6, 2008)]
[Notices]
[Pages 66053-66054]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-26432]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of 
the Recombinant DNA Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Recombinant DNA Advisory Committee.
    Date: December 3-4, 2008.
    Time: December 3, 2008, 9:30 a.m. to 5:30 p.m.
    Agenda: The Recombinant DNA Advisory Committee will review and 
discuss selected human gene transfer protocols as well as related 
data management activities. Please check the meeting agenda at http: 
//www4.od.nih.gov/oba/RAC/meeting.htm for more information.
    Place: National Institutes of Health, The Fishers Lane 
Conference Center, 5635 Fishers Lane, Terrace Level Conference Room, 
Rockville, MD 20852.

    Time: December 4, 2008, 8 a.m. to 1 p.m.
    Agenda: The Recombinant DNA Advisory Committee will review and 
discuss selected human gene transfer protocols including a gene 
transfer protocol for X-SCID as well as related data management 
activities. Please check the meeting agenda at http://
www4.od.nih.gov/oba/RAC/meeting.htm for more information.
    Place: National Institutes of Health, The Fishers Lane 
Conference Center, 5635 Fishers Lane, Terrace Level Conference Room, 
Rockville, MD 20852.
    Contact Person: Lisa A. Parker, Advisory Committee Coordinator, 
Office of Science Policy, Office of Biotechnology Activities, 
National Institutes of Health, 6705 Rockledge Drive, Suite 750-A1, 
Bethesda, MD 20892, 301-496-9838, parkerla@mail.nih.gov.
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: http://www4.od.nih.gov/oba/, where an agenda and any 
additional information for the meeting will be posted when 
available.
    OMB's ``Mandatory Information Requirements for Federal 
Assistance Program Announcements'' (45 FR 39592, June 11, 1980) 
requires a statement concerning the official government programs 
contained in the Catalog of Federal Domestic Assistance. Normally 
NIH lists in its announcements the number and title of affected 
individual programs for the guidance of the public. Because the 
guidance in this notice covers virtually every NIH and Federal 
research program in which DNA recombinant molecule techniques could 
be used, it has been determined not to be cost effective or in the 
public interest to attempt to list these programs. Such a list would 
likely require several additional pages. In addition, NIH could not 
be certain that every Federal program would be included as many 
Federal agencies, as well as private organizations, both national 
and international, have elected to follow the NIH Guidelines. In 
lieu of the individual program listing, NIH invites readers to 
direct questions to the information address above about whether 
individual programs listed in the Catalog of Federal Domestic 
Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research Enhancement Award; 93.936, NIH Acquired 
Immunodeficiency Syndrome Research Loan

[[Page 66054]]

Repayment Program; 93.187, Undergraduate Scholarship Program for 
Individuals from Disadvantaged Backgrounds, National Institutes of 
Health, HHS)

    Dated: October 30, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
 [FR Doc. E8-26432 Filed 11-5-08; 8:45 am]
BILLING CODE 4140-01-P